Description |
Dihydroisotanshinone I is a bioactive compound present in a widely used traditional Chinese medicine named danshen.
|
Target |
STAT3
|
In Vitro |
Dihydroisotanshinone I can inhibit the migration of both androgen-dependent and androgen-independent prostate cancer cells. Dihydroisotanshinone diminishes the ability of prostate cancer cells to recruit macrophages and reduces the secretion of chemokine (C-C motif) ligand 2 (CCL2) from both macrophages and prostate cancer cells in a dose-dependent manner. It inhibits the protein expression of p-STAT3 and decreases the translocation of STAT3 into nuclear chromatin. It also suppresses the expression of tumor epithelial-mesenchymal transition genes, including RhoA and SNAI1[1]. Pretreating the cells with dihydroisotanshinone I at concentrations ranging from 2.5 μM to 20 μM for 24 hours cause dose-dependent protection against hepatotoxicity induced by menadione. Adding dihydroisotanshinone I to freshly isolated hepatocytes at concentrations between 50 nM to 200 nM inhibit NADH-induced superoxide production dose-dependently[2].
|
Cell Assay |
Dihydroisotanshinone I is dissolved in ethyl acetate and mixed with the culture medium. The final concentration of ethyl acetate is 0.1% (v/v). Cell are treated with 2.5, 5, 10, and 20 μM dihydroisotanshinone I for 24 hours. The cell viability is measured using the MTT assay[2].
|
Density | 1.3±0.1 g/cm3 |
Boiling Point | 479.2±45.0 °C at 760 mmHg |
Flash Point | 214.9±28.8 °C |
Exact Mass | 278.094299 |
PSA | 43.37000 |
LogP | 3.90 |
Vapour Pressure | 0.0±1.2 mmHg at 25°C |